Clinical Trials Logo

Adverse Drug Reaction clinical trials

View clinical trials related to Adverse Drug Reaction.

Filter by:

NCT ID: NCT02838212 Completed - Clinical trials for Adverse Drug Reaction

Adverse Drug Reactions With Fatal Outcome

Start date: February 2016
Phase: N/A
Study type: Observational

The purpose of this study is to determine the incidence of drug-related deaths in a university hospital during the year 2015

NCT ID: NCT02559960 Suspended - Adverse Drug Event Clinical Trials

Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study

Start date: September 2015
Phase:
Study type: Observational

This registry aims to monitor the safety of Breviscapine Powder-Injection and to identify the potential risk factors for the adverse drug reactions.

NCT ID: NCT02297126 Completed - Clinical trials for Adverse Drug Reaction

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

INGenious
Start date: March 2015
Phase: N/A
Study type: Interventional

The INGenious trial will prospectively enroll a total of 6,000 patients, with 2,000 patients assigned to a pharmacogenetic testing arm and 4,000 to a control arm who will be followed, but not tested. It is randomized between an intervention arm and one that receives no intervention in order that the genotyped group can be compared with one in which undisturbed, routine clinical care is carried out in patients taking the same drugs. Both arms will be followed for a year after being prescribed a targeted medication. Patients randomized into the intervention arm that are prescribed one or more of the 24 targeted index medication will receive pharmacogenomic testing using a custom micro-array measuring 51 Single nucleotide polymorphisms in 16 genes. The study is being conducted by the Indiana University School of Medicine and the Indiana University Institute of Personalized Medicine in collaboration with the Eskenazi and Indiana University Health Systems and will evaluate the economic and clinical outcomes associated with embedding a pharmacogenomics program in a system that serves as the primary health care safety-net in Indianapolis, Indiana. By successfully implementing a pharmacogenomics program and integrating it with the Electronic Health Record and Clinical Decision Support system, physicians will be able to optimize patient care by delivering tailored therapeutic decisions based on the patient's individual genetics.

NCT ID: NCT02159209 Completed - Acute Kidney Injury Clinical Trials

The Drug Induced Renal Injury Consortium

DIRECT
Start date: February 2013
Phase: N/A
Study type: Observational

Some medications are known to cause kidney damage because the person is allergic to the medication while others cause direct damage to the kidney because they are toxic at certain concentrations. Risk factors for developing kidney damage have been identified for some medications but not for all. Patients who are exposed to these important medications and develop problems with their kidneys may have some genetic risk. The purpose of this study is to determine the genetic risk factors for drug induced kidney injury. A better understanding of the role of genetics for the development of kidney injury from medications will allow us to better select medications, improve effectiveness of treatment and minimize harm.

NCT ID: NCT02134587 Completed - Clinical trials for Adverse Drug Reaction

Educational Intervention in Pharmacovigilance for Hospital Health Professionals

EIPhv
Start date: February 2012
Phase: N/A
Study type: Interventional

Spontaneous reports by health professionals generate the signals in pharmacovigilance. However, the passive method has limitations and the most important of them are the underreporting and the poor quality of data, hindering the causality assessment of adverse drug events (ADE). Therefore, the present study aimed to validate an educational intervention (EI) in pharmacovigilance for hospital health professionals, in order to analyze the impact on the knowledge, skill and attitude in ADE reporting. Investigators proposed a multifaceted EI which will be developed in four meetings with one hour each. The following activities will be carried out: application of a questionnaire to assess the knowledge, skill and attitude before and after EI; lecture; practical class and education material distribution. The answers of questionnaire are going to be analyzed using content analysis technique. The definitions of World Health Organization and the minimum and desired criteria to fill the ADE form, according to the Pan American Health Organization, are going to be considered gold-standard answers. The statistical test of Wilcoxon-Mann Whitney test for paired samples will be applied, in order to assess the impact of educational intervention on behavior of health professionals (ADE reporting). With the present study, the following hypotheses will be tested: H0= There is no difference between the numbers of ADE reported (behavior/attitudes) before and after the educational intervention. H1= The numbers of ADE reported before and after the educational intervention are different.

NCT ID: NCT02094638 Completed - Clinical trials for Adverse Drug Reaction

Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study

Start date: January 2014
Phase: N/A
Study type: Observational [Patient Registry]

Tanreqing Injection is widely used in respiratory disease with Chinese medicine syndrome of retention of phlegm and heat in Fei. This study record clinical use of Tanreqing Injection in the real world, observe the adverse drug reactions/ adverse drug events during treatment, and figure out why Tanreqing induced severe allergic reaction happens.

NCT ID: NCT02012504 Recruiting - Clinical trials for Anxiety Disorders and Symptoms

Antidepressant Monotherapy on Depressive and Anxiety Symptom in Chinese Patients

Start date: June 2013
Phase: Phase 0
Study type: Observational

The primary objective is to evaluate the improvement of antidepressant monotherapy on depressive and anxiety symptom in Chinese patients who meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for the comorbidity of major depressive disorder (MDD) and generalized anxiety disorder (GAD)

NCT ID: NCT01946919 Completed - Stroke Clinical Trials

Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study

PACER
Start date: October 2012
Phase:
Study type: Observational [Patient Registry]

Cinepazide Maleate Injection is widely used in cerebrovascular disease in china. The safety of the cinepazide, especially the blood system, has not been fully evaluated in Chinese population. In order to improve the rational use of cinepazide, the investigators observe its clinical use in the real world in China, evaluate its safety and clinical benefit in a large Chinese population.

NCT ID: NCT01906710 Recruiting - Clinical trials for Adverse Drug Reaction

the Pharmacy Intervention Team Hospital-based (PITH) for People Study: Effect on Clinical and Economic Outcomes

PITH
Start date: January 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether a hospital pharmacy team (pharmacy technicians and pharmacists) together with (recently admitted) patients are able to diminish the number of drug related problems including adverse drug events, made before, during and after admissions resulting in reductions of re-hospitalizations and costs.

NCT ID: NCT01872520 Completed - Clinical trials for Adverse Drug Reaction

Post-marketing Safety Surveillance of the Injection of DanShenDuoFenSuanYan A Real World Study

Start date: June 2012
Phase: N/A
Study type: Observational [Patient Registry]

Magnesium Lithospermate B, the main constituent of the Injection of DanShenDuoFenSuanYan (the Injection of Depsides Salts From Salvia Miltiorrhiza), is the active ingredient of Salvia Miltiorrhiza. This study record clinical use of The injection of DanShenDuoFenSuanYan in the real world, and observe the adverse drug reactions/ adverse drug events during treatment.